Treatment with adalimumab in a patient with regenerative nodular hyperplasia secondary to azathioprine
Introduction: regenerative nodular hyperplasia (RNH) is a rare liver disease with an etiology that is not well understood. Among the etiological factors are purine-analogue drugs such as azathioprine. Case report: we present a case of a 47-year-old patient diagnosed with Crohn's disease in trea...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Aran Ediciones
2013-03-01
|
| Series: | Revista Espanola de Enfermedades Digestivas |
| Subjects: | |
| Online Access: | http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300009&lng=en&tlng=en |
| _version_ | 1811239712654884864 |
|---|---|
| author | Rafael León-Montañes Claudio Trigo-Salado Eduardo Leo-Carnerero María Dolores de-la-Cruz-Ramírez José Manuel Herrera-Justiniano José Luis Márquez-Galán |
| author_facet | Rafael León-Montañes Claudio Trigo-Salado Eduardo Leo-Carnerero María Dolores de-la-Cruz-Ramírez José Manuel Herrera-Justiniano José Luis Márquez-Galán |
| author_sort | Rafael León-Montañes |
| collection | DOAJ |
| description | Introduction: regenerative nodular hyperplasia (RNH) is a rare liver disease with an etiology that is not well understood. Among the etiological factors are purine-analogue drugs such as azathioprine. Case report: we present a case of a 47-year-old patient diagnosed with Crohn's disease in treatment with azathioprine due to corticosteroid dependency who developed RNH with clinical and laboratory signs of portal hypertension one year after starting treatment. After discontinuation of azathioprine, the patient started treatment and, given the poor disease progression, started treatment with adalimumab. This was continued with an excellent response and without deleterious effects on the liver. Discussion: the relevance of this case is twofold: First, this is a rare and early side effect of azathioprine treatment and this is an irreversible disease with potentially serious complications. Second, because treatment was carried out with biological drugs (adalimumab) despite the patient having advance liver disease with portal hypertension without any evidence of its worsening, nor signs of deleterious effects or complications, given that there is scarce or no experience with adalimumab treatment in this type of situation. |
| first_indexed | 2024-04-12T13:05:59Z |
| format | Article |
| id | doaj.art-73f5a8a234ef462690fa913c2f06573f |
| institution | Directory Open Access Journal |
| issn | 1130-0108 |
| language | English |
| last_indexed | 2024-04-12T13:05:59Z |
| publishDate | 2013-03-01 |
| publisher | Aran Ediciones |
| record_format | Article |
| series | Revista Espanola de Enfermedades Digestivas |
| spelling | doaj.art-73f5a8a234ef462690fa913c2f06573f2022-12-22T03:32:02ZengAran EdicionesRevista Espanola de Enfermedades Digestivas1130-01082013-03-01105316817010.4321/s1130-01082013000300009S1130-01082013000300009Treatment with adalimumab in a patient with regenerative nodular hyperplasia secondary to azathioprineRafael León-Montañes0Claudio Trigo-Salado1Eduardo Leo-Carnerero2María Dolores de-la-Cruz-Ramírez3José Manuel Herrera-Justiniano4José Luis Márquez-Galán5Hospital Universitario Virgen del RocíoHospital Universitario Virgen del RocíoHospital Universitario Virgen del RocíoHospital Universitario Virgen del RocíoHospital Universitario Virgen del RocíoHospital Universitario Virgen del RocíoIntroduction: regenerative nodular hyperplasia (RNH) is a rare liver disease with an etiology that is not well understood. Among the etiological factors are purine-analogue drugs such as azathioprine. Case report: we present a case of a 47-year-old patient diagnosed with Crohn's disease in treatment with azathioprine due to corticosteroid dependency who developed RNH with clinical and laboratory signs of portal hypertension one year after starting treatment. After discontinuation of azathioprine, the patient started treatment and, given the poor disease progression, started treatment with adalimumab. This was continued with an excellent response and without deleterious effects on the liver. Discussion: the relevance of this case is twofold: First, this is a rare and early side effect of azathioprine treatment and this is an irreversible disease with potentially serious complications. Second, because treatment was carried out with biological drugs (adalimumab) despite the patient having advance liver disease with portal hypertension without any evidence of its worsening, nor signs of deleterious effects or complications, given that there is scarce or no experience with adalimumab treatment in this type of situation.http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300009&lng=en&tlng=enHiperplasia nodular regenerativaAdalimumabAzatioprina |
| spellingShingle | Rafael León-Montañes Claudio Trigo-Salado Eduardo Leo-Carnerero María Dolores de-la-Cruz-Ramírez José Manuel Herrera-Justiniano José Luis Márquez-Galán Treatment with adalimumab in a patient with regenerative nodular hyperplasia secondary to azathioprine Revista Espanola de Enfermedades Digestivas Hiperplasia nodular regenerativa Adalimumab Azatioprina |
| title | Treatment with adalimumab in a patient with regenerative nodular hyperplasia secondary to azathioprine |
| title_full | Treatment with adalimumab in a patient with regenerative nodular hyperplasia secondary to azathioprine |
| title_fullStr | Treatment with adalimumab in a patient with regenerative nodular hyperplasia secondary to azathioprine |
| title_full_unstemmed | Treatment with adalimumab in a patient with regenerative nodular hyperplasia secondary to azathioprine |
| title_short | Treatment with adalimumab in a patient with regenerative nodular hyperplasia secondary to azathioprine |
| title_sort | treatment with adalimumab in a patient with regenerative nodular hyperplasia secondary to azathioprine |
| topic | Hiperplasia nodular regenerativa Adalimumab Azatioprina |
| url | http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300009&lng=en&tlng=en |
| work_keys_str_mv | AT rafaelleonmontanes treatmentwithadalimumabinapatientwithregenerativenodularhyperplasiasecondarytoazathioprine AT claudiotrigosalado treatmentwithadalimumabinapatientwithregenerativenodularhyperplasiasecondarytoazathioprine AT eduardoleocarnerero treatmentwithadalimumabinapatientwithregenerativenodularhyperplasiasecondarytoazathioprine AT mariadoloresdelacruzramirez treatmentwithadalimumabinapatientwithregenerativenodularhyperplasiasecondarytoazathioprine AT josemanuelherrerajustiniano treatmentwithadalimumabinapatientwithregenerativenodularhyperplasiasecondarytoazathioprine AT joseluismarquezgalan treatmentwithadalimumabinapatientwithregenerativenodularhyperplasiasecondarytoazathioprine |